James M. Ahlers - 30 Jul 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Chief Financial Officer
Issuer ticker: CUE
Reported as of: 30 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Aug 2026, 16:19:19 UTC
Prior SEC filing: 29 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Michael Meluzio, Attorney-in-Fact

Key filing fact

James M. Ahlers filed Form 4 for Cue Biopharma, Inc. (CUE) on 03 Aug 2026.

Key facts

This page summarizes James M. Ahlers's Form 4 filing for Cue Biopharma, Inc. (CUE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Aug 2026, 16:19.

Change

Previous filing in this sequence was filed on 29 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001320383 Primary reporting owner

Ahlers James M

Relationship: Chief Financial Officer
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Michael Meluzio, Attorney-in-Fact
Signature date: 03 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CUE transaction

Common Stock

Award

Transaction value
Shares: +25,500
Change %
Price: $0.000000^*
Shares after: 25,500
Date: 30 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +51,000
Change %
Price: $0.000000^*
Shares after: 51,000
Date: 30 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,000
Exercise price: $30.40
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.

Footnote F2

The stock option becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.